3 YEARS IN, PROGRAM BUILDS ON CAPABILITY AND CONNECTIVITY FOR EARLY CAREER RESEARCHERS IN ENT MEDICAL DEVICES Beyond Science gives in theatre opportunities, networking with stakeholders and support from mentors
With
Professor Payal Mukherjee, Adult and Paediatric ENT Surgeon
Otologist, Cochlear Implant and Skull Base Surgeon &
Clinical Professor, Macquarie University &
TGA Advisory Committee for Medical Devices &
Clinical Associate Professor, University of Sydney &
Surgical Innovation Lead, RPA Institute of Academic Surgery &
Head of Department ENT, Sydney Adventist Hospital &
Co-Founder & Co-Director, Beyond Science
Distinguished Professor Gordon Wallace AO,
Director, Intelligent Polymer Research Institute,
University of Wollongong &
Co-Founder & Co-Director, Beyond Science
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Sydney & Wollongong | August 2025
Surgeon-scientists and surgeon-innovators have an important role in the entire medical technology translational cycle; not only from discovery to commercialisation, but in ensuring that health technologies are implemented in value-based manner.
This includes defining safety and regulatory standards, balancing patient outcomes against health care costs, and working with policy makers to ensure that funding is both sustainable and promotes equitable access to technology.
Despite a rich history of biomedical innovation in Australia, there are limited training opportunities for surgeons to develop these skills. Within NSW, there are no formal surgeon-scientist training pathways in Otolaryngology, Head and Neck Surgery.
In 2022, Distinguished Professor Gordon Wallace AO and Professor Mukherjee jointly established Beyond Science as a clinician led, academically supported and clinician run Australian-first medical technology translation program.
The program is aimed at early career researchers and clinician-scientists working in medical device research specifically in otolaryngology (ear, nose, and throat), head and neck surgery.
Its core mission is to build capability and foster connections between researchers and key stakeholders such as industry, government, universities, and health systems.
This is through helping researchers understand health system priorities and translation pathways from research to real-world impact. Uniquely, this includes opportunity to enter surgical environments for observation and tissue collection.
Australian Health Journal spoke to its founders about how it supports academic mentorship and creates networking opportunities to help early career stage medical device researchers connect with clinicians, policymakers, industry leaders, and funding bodies.
Beyond Science is funded by Passe & Williams Foundation & the Sydney Local Health District
Source: Adapted from Beyond Science, RACS and University of Wollongong websites
-
Landmark Australian-led study revises thresholds to diagnose and treat anaemia
In 2014, WEHI researchers began a study at the request of the World Health Organization (WHO), to formally review its global anaemia guidelines that were last updated in 1968.
Study lead and Acting WEHI Deputy Director, Professor Sant-Rayn Pasricha, speaking to Australian Health Journal said while anaemia can be diagnosed by measuring the amount of haemoglobin in the blood, there is currently no consensus on the thresholds that should be used to define the condition. -
Taiwanese health and research delegation visit Paratus clinical trial site in Canberra
In late August 2025, a Taiwanese delegation comprising government officials from the Taiwanese FDA, various governmental groups, and physicians and researchers from across Taiwan, visited Paratus Clinical’s trial site in Canberra. Their objective was to explore both the differences and similarities between the clinical research ecosystems of Taiwan and Australia.
-
Gaining a better understanding of perimenopause and menopause
Nearly half of women seeking help for menopause symptoms are already experiencing clinically significant distress by the time they ask for support, according to a recent national benchmark report released by Metluma.
The 2026 Australian Menopause Experience Report, based on insights from 1,468 women using Metluma’s UMA40 assessment tool, found 43% triggered at least one clinical red flag at baseline (referral to a doctor within 24-48 hours), with more than one in five presenting with multiple red flags linked to more complex symptom burden.
